omni
aaps
How Might Biopharma Manufacturing Differ In The Next Decade?
How Might Biopharma Manufacturing Differ In The Next Decade?
When embarking on our pulling together the manufacturing outlook article for our December 2017 issue, we faced what many might describe as a good problem to have - too much content and not enough pages.
Drug Policy: The Year In Review, And The Year Ahead
Drug Policy: The Year In Review, And The Year Ahead
Last year was an unquestionably busy time for health care news of all kinds.
Great Expectations: The Psychology of Switching From Brand Drugs To Generics
Great Expectations: The Psychology of Switching From Brand Drugs To Generics
The late Canadian novelist Robertson Davies once remarked that the eye sees only what the mind is prepared to comprehend. He could almost have been referring to oft-reported negative experiences of patients switching from branded to generic drugs.
FDA Calls For Industry Input On Continuous Manufacturing Guidelines
FDA Calls For Industry Input On Continuous Manufacturing Guidelines
The FDA clearly wants more companies to transition to continuous manufacturing (CM), highlighting the approach's benefits in a blog post published.
The Why, How And When Of AI In The Pharmaceutical Industry
The Why, How And When Of AI In The Pharmaceutical Industry
Recently, pharmaceutical companies have been demonstrating a vivid interest in artificial intelligence (AI) applications for various research needs, catalyzed by the illustrative practical achievements of AI in solving more "traditional" tasks - overco...